Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...

Royalty Pharma will present at the 43rd Annual J.P. Morgan Healthcare Conference at 6:45 p.m. ET / 3:45 p.m. PT on January 14, 2025. The webcast will be accessible from Royalty Pharma’s “Events” page ...

Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the BoardInterim Changes to ...

Kotak Strategic Situations India Fund II invests ₹940 crore in Neuberg Diagnostics for expansion and IPO preparation.

Neuberg Diagnostics, a Chennai-based diagnostics chain, has secured Rs 940 crore from Kotak Alt, becoming the largest ever ...

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The ...

Kotak Strategic Situations India Fund II, managed by Kotak Alternate Asset Managers Limited (Kotak Alt), has announced an ...

Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of greater than $100 million in 2026 growing to over $175 ...

Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors ...

Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — one of the five large pharmas backing Mediar – will pay ...